IAM
SWTX

Innovis Asset Management’s SpringWorks Therapeutics SWTX Stock Holding History

Innovis Asset Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8,613
Closed -$226K – 177
2023
Q2 		$226K Buy
+8,613
New +$226K 0.08% 145

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Innovis Asset Management's SWTX Position: Q3 2023 in Review

Innovis Asset Management sold out of SpringWorks Therapeutics (SWTX) in Q3 2023, closing a stake of 8,613 shares — an estimated $226K sold.

Innovis Asset Management first reported a position in SWTX in Q2 2023 and held it in 1 quarter. The position peaked at $226K in Q2 2023. 147 funds tracked by Wall St. Rank hold SWTX as of Q3 2023.

  • Innovis Asset Management reported no remaining SpringWorks Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Innovis Asset Management sold 8,613 SpringWorks Therapeutics shares in Q3 2023, an estimated $226K.
  • Innovis Asset Management first reported a position in SpringWorks Therapeutics in Q2 2023 and held it in 1 quarter.
  • Innovis Asset Management's SpringWorks Therapeutics position peaked at $226K in Q2 2023.
  • 147 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2023.

Based on Innovis Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.